[go: up one dir, main page]

AU637049B2 - Recombinant flagellin vaccines - Google Patents

Recombinant flagellin vaccines Download PDF

Info

Publication number
AU637049B2
AU637049B2 AU36979/89A AU3697989A AU637049B2 AU 637049 B2 AU637049 B2 AU 637049B2 AU 36979/89 A AU36979/89 A AU 36979/89A AU 3697989 A AU3697989 A AU 3697989A AU 637049 B2 AU637049 B2 AU 637049B2
Authority
AU
Australia
Prior art keywords
recombinant
flagellin
epitope
gene
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU36979/89A
Other languages
English (en)
Other versions
AU3697989A (en
Inventor
William Robert Marjarian
Salete Maria Cardozo Newton
Bruce Arnold Dunbar Stocker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Leland Stanford Junior University
Original Assignee
Praxis Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biologics Inc filed Critical Praxis Biologics Inc
Publication of AU3697989A publication Critical patent/AU3697989A/en
Application granted granted Critical
Publication of AU637049B2 publication Critical patent/AU637049B2/en
Assigned to AMERICAN CYANAMID COMPANY, BOARD OF TRUSTEES FOR THE LELAND STANFORD JUNIOR UNIVERSITY, THE reassignment AMERICAN CYANAMID COMPANY Alteration of Name(s) in Register under S187 Assignors: BOARD OF TRUSTEES FOR THE LELAND STANFORD JUNIOR UNIVERSITY, THE, PRAXIS BIOLOGICS, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445Plasmodium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU36979/89A 1988-05-05 1989-05-05 Recombinant flagellin vaccines Ceased AU637049B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US190570 1980-09-25
US19057088A 1988-05-05 1988-05-05

Publications (2)

Publication Number Publication Date
AU3697989A AU3697989A (en) 1989-11-29
AU637049B2 true AU637049B2 (en) 1993-05-20

Family

ID=22701885

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36979/89A Ceased AU637049B2 (en) 1988-05-05 1989-05-05 Recombinant flagellin vaccines

Country Status (10)

Country Link
EP (1) EP0419513B1 (fr)
JP (1) JP2793673B2 (fr)
AT (1) ATE121782T1 (fr)
AU (1) AU637049B2 (fr)
CA (1) CA1340817C (fr)
DE (1) DE68922394T2 (fr)
DK (1) DK263390A (fr)
FI (1) FI104638B (fr)
NO (1) NO302031B1 (fr)
WO (1) WO1989010967A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU660945B2 (en) * 1990-10-01 1995-07-13 Minister for Agriculture, Fisheries and Food in Her Britannic Majesty's Government of The United Kingdom of Great Britain and Northern Ireland, The Salmonella polynucleotide sequence

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US6861212B1 (en) 1987-11-18 2005-03-01 Chiron Corporation NANBV diagnostics and vaccines
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
JP3436756B2 (ja) * 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスiの外膜タンパク質のワクチン
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
ATE190656T1 (de) * 1990-10-01 2000-04-15 Mini Agriculture & Fisheries Verfahren zur prüfung für salmonella
GB9101550D0 (en) * 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
IL101639A0 (en) * 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
DE60011560T2 (de) * 1999-12-28 2005-08-18 Akzo Nobel N.V. Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
JPWO2004055045A1 (ja) * 2002-12-16 2006-04-20 株式会社シーエーエフラボラトリーズ サルモネラ抗原処方物、それを使用した抗体検査キット及びサブユニットワクチン
US20080248068A1 (en) 2004-05-07 2008-10-09 Hans-Gustaf Ljunggren Use of Flagellin as an Adjuvant for Vaccine
JP2008521431A (ja) * 2004-12-02 2008-06-26 シーエスアイアール 破壊されたフラゲリン遺伝子を含むグラム陽性細菌細胞、フラゲリンベースの融合タンパク質及び金属イオンの液体からの除去における使用
CA2589556A1 (fr) 2004-12-16 2006-08-03 Wake Forest University Health Sciences Utilisation de flagelline en immunotherapie antitumorale
AU2006206647C1 (en) 2005-01-19 2011-01-20 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
EP2476432B1 (fr) 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions incluant de l'hémagglutinine, procédés pour leur fabrication et leurs méthodes d'utilisation
WO2009128951A2 (fr) 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions de protéines du virus respiratoire syncytial et leurs méthodes d'utilisation
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CN102816246B (zh) * 2012-09-04 2014-07-23 成都蓉生药业有限责任公司 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途
WO2016046357A1 (fr) 2014-09-26 2016-03-31 Bavarian Nordic A/S Procédés et compositions pour l'immunisation intra-nasale avec un mva recombinant codant pour une flagelline
EP3221464B1 (fr) * 2014-11-18 2022-02-23 The Trustees of Columbia University in the City of New York Détection d'analytes à l'aide de cellules vivantes
CN104402974B (zh) * 2014-12-10 2017-11-14 重庆医科大学 一种具有粘膜免疫佐剂活性的多肽及其在制备粘膜免疫佐剂中的用途
US10849938B2 (en) 2017-09-13 2020-12-01 ZBiotics Company Gene expression system for probiotic microorganisms
US10806778B2 (en) * 2019-01-30 2020-10-20 Prokarium Limited Modified strain of Salmonella enterica Typhi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
WO1987002385A1 (fr) * 1985-10-11 1987-04-23 Genetics Institute, Inc. Procede de production de proteines heterologues
US4886748A (en) * 1986-03-11 1989-12-12 Shionogi & Co., Ltd. DNA encoding flagellin and vector having the same
CA1331355C (fr) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentialisation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU660945B2 (en) * 1990-10-01 1995-07-13 Minister for Agriculture, Fisheries and Food in Her Britannic Majesty's Government of The United Kingdom of Great Britain and Northern Ireland, The Salmonella polynucleotide sequence

Also Published As

Publication number Publication date
EP0419513B1 (fr) 1995-04-26
CA1340817C (fr) 1999-11-09
WO1989010967A1 (fr) 1989-11-16
ATE121782T1 (de) 1995-05-15
DK263390D0 (da) 1990-11-02
DE68922394D1 (de) 1995-06-01
DE68922394T2 (de) 1995-10-05
NO904806D0 (no) 1990-11-05
FI104638B (fi) 2000-03-15
NO904806L (no) 1991-01-03
JPH04502402A (ja) 1992-05-07
AU3697989A (en) 1989-11-29
FI905441A0 (fi) 1990-11-02
DK263390A (da) 1991-01-04
NO302031B1 (no) 1998-01-12
EP0419513A1 (fr) 1991-04-03
JP2793673B2 (ja) 1998-09-03

Similar Documents

Publication Publication Date Title
US6130082A (en) Recombinant flagellin vaccines
AU637049B2 (en) Recombinant flagellin vaccines
US5112749A (en) Vaccines for the malaria circumsporozoite protein
EP0652962B1 (fr) Expression de proteines recombinantes fusionnees dans des bacteries attenuees
Wu et al. Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of Salmonella.
JP5566684B2 (ja) Clostridiumdifficileに対する、組換え毒素A/毒素Bワクチン
EP0672116B1 (fr) Mutants de deletion utilises en tant que vaccins contre le cholera
Olive et al. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens
US5708155A (en) Enhanced immunogenicity using leukotoxin chimeras
Barry et al. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908
CN101180312A (zh) 来自尿路病原性大肠杆菌的免疫原
US5422110A (en) Enhanced immunogenicity using leukotoxin chimeras
WO1992005192A1 (fr) Epitopes des lymphocytes t
US6096320A (en) Vaccines with chimeric protein comprising gamma-interferon and leukotoxin derived from pasteurella haemolytica
LeClerc et al. Induction of virus-neutralizing antibodies by bacteria expressing the C3 poliovirus epitope in the periplasm. The route of immunization influences the isotypic distribution and the biologic activity of the antipoliovirus antibodies.
Stocker Aromatic-dependent Salmonella as live vaccine presenters of foreign epitopes as inserts in flagellin
Schmidt et al. Synthetic peptides corresponding to protective epitopes of Escherichia coli digalactoside-binding pilin prevent infection in a murine pyelonephritis model.
US5273889A (en) Gamma-iterferon-leukotoxin gene fusions and uses thereof
US5874088A (en) Deletion mutants of cholera vaccines expressing heterologous antigens
US7235245B2 (en) Chimeric lyssavirus nucleic acids and polypeptides
Alves et al. Epitope specificity of antibodies raised against enterotoxigenic Escherichia coli CFA/I fimbriae in mice immunized with naked DNA
US6797272B1 (en) Enhanced immunogenicity using leukotoxin chimeras
AU617402B2 (en) Vaccines for malaria
Makoff et al. Recombinant Antigens as Components of a Diphtheria-Tetanys-PerSüssis Vaccine
WO1994006911A2 (fr) Antigenes de mycoplasma pulmonis, et procedes et compositions destines a etre utilises dans le clonage et la vaccination